Ontology highlight
ABSTRACT: Background
Everolimus is beneficial for patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC). However, some patients developed drug resistance and the well-established predictor for everolimus efficacy was limited.Objectives
The study was designed to evaluate the efficacy of everolimus in different treatment lines and identify several clinicopathological markers to estimate everolimus efficacy in patients with HR+/HER2- ABC.Design
This was a retrospective and multicenter study.Methods
Between 2014 and 2022, more than 2000 patients with tumors who received everolimus were collected from multiple cancer centers in China (National Cancer Center, Chinese PLA General Hospital, Pekin
SUBMITTER: Tan Y
PROVIDER: S-EPMC11569487 | biostudies-literature | 2024
REPOSITORIES: biostudies-literature